法罗培南钠与头孢泊肟酯口服治疗急性细菌性感染的最小成本分析  

Cost-minimization Analysis on Oral Faropenem sodium and Cefodoxime axetil in the Treatment of Acute Bacterial infections

作　　者：陈蓉[1] 王诗红[1] 欧敏华[1] 

机构地区：[1]遵义医学院第五附属珠海医院,广东珠海519100

出　　处：《中国现代应用药学》2008年第4期360-362,共3页Chinese Journal of Modern Applied Pharmacy

摘　　要：目的评价法罗培南钠片与头孢泊肟酯片治疗急性细菌性感染的经济学效果。方法根据文献资料,对法罗培南钠片(试验组)与孢泊肟酯片(对照组)治疗226例急性细菌性感染的方案进行最小成本分析。结果对照组、试验组成本分别为(811.64±136.66)元、(1011.13±187.96)元;总有效率分别为95.54%、95.61%;成本-效果比分别为(8.50±1.43)、(10.58±1.97)。结论头孢泊肟酯治疗急性细菌性感染相对于法罗培南钠具有明显的药物经济学优势。OBJECTIVE To evaluate the economic-effectiveness of oral faropenem sodium and cefodoxime axetil for acute bacterial infections. METHODS Referenced by the related literature, the cost - minimization of the regimes of faropenem sodium （trial group） and cefodoxime axetil （control group） in treating 226 patients with acute bacterial infections were evaluated. RESULTS The costs of the control group and the trial group were （811.64± 136.66） yuan and （ 1011.13 ± 187.96） yuan, respectively. The effective rates were 95.54% and 95.61%, respectively. The cost effectiveness ratios were （ 8.50 ± 1.43 ） and （ 10.58 ± 1.97 ）, respectively. CONCLUSION The therapy of cefodoxime axetil has marked pharmacoeconomics advantage over faropenem sodium in treating acute bacterial infections.

关 键 词：急性细菌性感染 法罗培南钠 头孢泊肟酯 最小成本分析 

分 类 号：R956[医药卫生—药学] R978.11